Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

NCT03892161 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Risks to participation

Conditions

HIV Infections

Interventions

DRUG: Darunavir/ritonavir 800/100 mg tablet
DRUG: Rifampicin 600mg QD tablet and DTG 50mg BD

Sponsor

University of Cape Town

Collaborators

[object Object]
[object Object]